Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.

Abstract

We performed a retrospective analysis of the European Group for Blood and Marrow Transplantation database comparing the outcomes of multiple myeloma patients who received tandem autologous followed by allogeneic PSCT (auto-allo) with the outcomes of patients who underwent a reduced intensity conditioning allograft (early RIC) without prior autologous transplant. From 1996 to 2013, we identified a total of 690 patients: 517 patients were planned to receive auto-allo and 173 received an early RIC allograft without prior autologous transplant. With a median follow-up of 93 months, 5-year PFS survival was significantly better in the auto-allo group, 34% compared with 22% in the early RIC group (P<0.001). OS was also significantly improved in the auto-allo group with a 5-year rate of 59% vs 42% in the early RIC group (P=0.001). The non-relapse mortality rate was lower in the auto-allo group than in the early RIC group, with 1- and 3-year rates of 8% and 13% vs 20% and 28%, respectively (P<0.001). The relapse/progression rate was similar in the two groups, with 5-year rates of 50% for auto-allo and 46% for early RIC (P=0.42). These data suggest that planned tandem autologous allograft can improve overall survival compared with upfront RIC allograft alone in patients with multiple myeloma.

• Authors: F Sahebi, S Iacobelli, A V Biezen, L Volin, P Dreger, M Michallet, P T Ljungman, T de Witte, A Henseler, N P M Schaap, L López-Corral, X Poire, J Passweg, R-M Hamljadi, S H Thomas, S Schonland, G Gahrton, C Morris, N KrÖger, L Garderet
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 50 Issue 6 Pg. 802-7 (Jun 2015) ISSN: 1476-5365 [Electronic] England
• PMID: 25798673 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)

Topics

• Adult
• Aged
• Allografts
• Autografts
• Disease-Free Survival
• Female
• Follow-Up Studies
• Hematopoietic Stem Cell Transplantation
• Humans
• Male
• Middle Aged
• Multiple Myeloma (mortality, therapy)
• Retrospective Studies
• Survival Rate